AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Purple Biotech Launches Phase 2 Trial for NT219 in Head and Neck Cancer Treatment
ByAinvest
Wednesday, Jun 18, 2025 5:20 am ET1min read
Purple Biotech has initiated a Phase 2 trial to evaluate NT219 in patients with head and neck cancer. The trial will assess the efficacy of NT219 when combined with pembrolizumab or cetuximab. NT219 targets oncogenic pathways IRS1/2 and STAT3, promoting degradation and inhibiting phosphorylation. The trial will also identify potential biomarkers for NT219.
Purple Biotech (NASDAQ/TASE: PPBT) has initiated a Phase 2 clinical study of NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study, conducted at the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with either pembrolizumab or cetuximab [1]. NT219 is a novel small molecule that targets the IRS1/2 and STAT3 pathways, promoting degradation and inhibiting phosphorylation, respectively [2].The Phase 2 trial employs a Simon 2-stage design with two treatment arms, initially enrolling 10 patients per arm with potential expansion to 29 patients per arm. The trial builds on promising Phase 1 results, which showed two partial responses and five stable disease cases when NT219 was combined with cetuximab [3]. The study aims to assess the efficacy of NT219 in combination with either pembrolizumab or cetuximab, both of which are standard-of-care treatments for R/M SCCHN patients.
The trial also focuses on identifying potential biomarkers for NT219, which could improve patient selection and increase response rates. The $5 billion projected market size for SCCHN treatments by 2030 indicates substantial commercial potential if NT219 demonstrates efficacy in this Phase 2 study [1].
References:
[1] https://www.stocktitan.net/news/PPBT/purple-biotech-announces-initiation-of-phase-2-study-of-nt219-in-u5sq2764o7cj.html
[2] https://www.gurufocus.com/news/2930633/purple-biotech-ppbt-kicks-off-phase-2-trial-for-nt219-in-head-and-neck-cancer-ilppbt-stock-news
[3] https://www.tipranks.com/news/the-fly/purple-biotech-announces-initiation-of-phase-2-study-of-nt219-thefly
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet